Skip to main content
Prof. Hartmann interviewed by Dr. Barbara Kreppel for 'Angewandte Nuklearmedizin'

Publication

Immunology and Nuclear Medicine

Prof. Gunther Hartmann was interviewed for the magazine “Angewandte Nuklearmedizin” and answered questions about immunology and nuclear medicine.

Dr. Barbara Kreppel from the magazine “Angewandte Nuklearmedizin” interviewed Prof. Gunther Hartmann, director of the Institute of Clinical Chemistry and Clinical Pharmacology and founding speaker of the ImmunoSensation2 Cluster of Excellence, on his expertise on immunology and nuclear medicine. 

During the interview, Prof. Gunther Hartmann shed light on emerging trends in the research fields of immune-oncology and autoimmunity, emphasizing the potential of nuclear medicine for the development of diagnostic tools and novel therapies. He gave an interesting perspective on how nuclear medicine advancements could help with cancer therapy and highlighted the importance of nuclear medicine for immune imaging.

The full interview can be found in the latest issue of “Angewandte Nuklearmedizin”.

Interview:

Angewandte Nuklearmedizin 2024; 47: 78–79
DOI 10.1055/a-2183-2133
ISSN 2749-7445
© 2024. Thieme. All rights reserved.
Georg Thieme Verlag KG, Rüdigerstraße 14,
70469 Stuttgart, Germany

Press contact:

Dr. Barbara Kreppel
Universitätsklinikum Bonn
Klinik und Poliklinik für Nuklearmedizin
Venusberg-Campus 1
53127 Bonn
E-Mail: barbara.kreppel@ukbonn.de

Related news

Tracking glioblastoma cell spread in human brain tissue

Publication

Core2Edge: How tumor cells conquer the brain

—Glioblastoma is an aggressive brain tumor that infiltrates deep into the surrounding brain tissue. Even after surgery, tumor cells remain in the brain and the tumor recurs. Bonn researchers have now developed Core2Edge, a model based entirely on human tissue that captures these hard-to-access infiltration zones at the tumor margin. The model enables investigation of the invasive front and direct assessment of new drug candidates in human tissue - without the need for animal testing. The study of the Brain Tumor Translational Research Group has now been published in Nature Protocols.
View entry
Mikrochip zur Wiederherstellung zentralen Sehvermögens bei fortgeschrittener Makuladegeneration.

Publication

Approval of a Novel Retinal Implant Technology

—A novel retinal implant is offering people with geographic atrophy the opportunity to regain part of their central vision for the first time. Geographic atrophy is a severe late stage of age-related macular degeneration. An international research team led by Prof. Frank G. Holz of the UKB and the University of Bonn demonstrated in an international clinical trial that the majority of participants experienced significant improvements in visual acuity. The novel retinal implant technology has now received approval for routine clinical use in Europe, making it available beyond clinical trials.
View entry
Authors

Publication

The Gut as a Key Player in Immunotherapy for MS

—B-cell depletion therapies, in which B cells of the immune system, which may drive disease activity in multiple sclerosis (MS), are temporarily removed, have contributed significantly to improved treatment for patients in recent years. Researchers from Bonn, along with their collaborators, have uncovered a previously unknown mechanism through which B-cell depletion therapies contribute to a better disease course in patients with MS. Surprisingly, the treatment appears to exert part of its beneficial effect by mobilizing regulatory immune cells that naturally reside in the gut.
View entry

Back to the news overview